| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/27/2009 | US7482372 Antiinflammatory; cartilage protecting therapeutics; antiarthritic agent; N-{4-[(2-methyl-4-quinolinyl)methoxy]phenyl}-2,4-dioxo-1,3-diazaspiro[4.5]decane-6-carboxamide; 2-(2,5-dioxo-4-imidazolidinyl)-N-{4-[(2-methyl-4-quinolinyl)methoxy]phenyl)acetamide |
| 01/27/2009 | US7482331 Treating myocardial failure in a human by administering an effective amount of a transgene encoding for alpha-MHC, wherein expression of alpha-MHC provides improvement in left ventricular ejection fraction |
| 01/27/2009 | US7482325 Downregulation of immune response by administering B7RP-2 fusion protein |
| 01/27/2009 | US7482320 Modulation of smooth muscle cell proliferation |
| 01/27/2009 | US7482025 Biomaterial derived from vertebrate liver tissue |
| 01/27/2009 | US7482024 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 01/27/2009 | US7482020 for making an adjuvanted vaccine comprising host albumin. The process comprises mixing host serum or host serum with an antigen, and then mixing the resulting mixture with an adjuvant. |
| 01/27/2009 | US7482007 Methods of inhibiting angiogenesis to treat cancer with alphavbeta3-specific antibodies |
| 01/27/2009 | CA2418167C Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 01/27/2009 | CA2415442C Novel .beta. crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same |
| 01/27/2009 | CA2399856C Antibiotic composition with inhibitor |
| 01/27/2009 | CA2395226C Devices for the delivery of drugs having antiprogestinic properties |
| 01/27/2009 | CA2377126C Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/27/2009 | CA2362499C Combinations of formoterol and mometasone furoate for asthma |
| 01/27/2009 | CA2338066C Treatment of dyskinesia |
| 01/22/2009 | WO2009012425A2 Compositions including leukotriene antagonists and nsaids and methods of using the same |
| 01/22/2009 | WO2009012357A2 Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| 01/22/2009 | WO2009011451A1 Solid preparation comprising alogliptin and metformin hydrochloride |
| 01/22/2009 | WO2009010529A1 Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
| 01/22/2009 | WO2009010492A2 Combinations comprising telmisartan and an anticholinergic such as tiotropium or a glycopyrronium salt for the treatment of respiratory diseases such as copd or asthma |
| 01/22/2009 | WO2008076447A3 Treatments of therapy-resistant diseases comprising drug combinations |
| 01/22/2009 | WO2008063558A3 Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| 01/22/2009 | WO2008026075A3 Treatment of intracellular bacterial infections with a protein kinase inhibitor or an as160 polypeptide activator |
| 01/22/2009 | WO2007126816A3 Methods and compositions for vaccination of poultry |
| 01/22/2009 | US20090023776 Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| 01/22/2009 | US20090023665 Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof |
| 01/22/2009 | US20090023659 Using cell surface adhesion proteins specific immunoglobulin to target therapeutics to tumorous; immunodiagnostics; immunotherapy |
| 01/22/2009 | US20090023639 Methods of Treatment |
| 01/22/2009 | US20090023224 Vascular endothelial growth factor 2 |
| 01/22/2009 | US20090023160 Antibodies specific for CYP1B1 |
| 01/22/2009 | US20090023152 Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 01/22/2009 | US20090023147 Diagnostics and therapeutics for osteoporosis |
| 01/22/2009 | US20090023145 Methods of diagnosing or prognosing Alzheimer's disease |
| 01/22/2009 | US20090022825 Method for Predicting Whether Subjects With Mild Cognitive Impairment (MCI) Will Develop Alzheimer's Disease |
| 01/22/2009 | US20090022815 Halogenated composition, method for preparing same and uses thereof |
| 01/22/2009 | US20090022796 Novel Substituted Benzimidazole Dosage Forms and Method of Using Same |
| 01/22/2009 | US20090022725 antagonist antibody that blocks binding of IL-17; degenerative cartilaginous disorders and other inflammatory diseases |
| 01/22/2009 | US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022707 contacting target cells with a therapeutic quantity of a soluble antibody that specifically binds tumor necrosis factor-related apoptosis inducing ligand receptor(TRAIL) DR5, and contacting target cells with a therapeutic agent |
| 01/22/2009 | US20090022686 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome |
| 01/22/2009 | US20090022658 Modified antibodies and methods of use |
| 01/22/2009 | CA2694620A1 Solid preparation comprising alogliptin and metformin hydrochloride |
| 01/22/2009 | CA2693144A1 Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| 01/22/2009 | CA2692655A1 Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
| 01/22/2009 | CA2688669A1 New combinations for the treatment of respiratory diseases |
| 01/21/2009 | EP2017355A1 Gene associated with arteriosclerotic disease, and use thereof |
| 01/21/2009 | EP2017337A1 Human tumor necrosis factor receptors |
| 01/21/2009 | EP2017279A1 Novel aminopyridine derivative having aurora-a-selective inhibitory activity |
| 01/21/2009 | EP2017263A1 Heteroarylamide lower carboxylic acid derivative |
| 01/21/2009 | EP2016953A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 01/21/2009 | EP2016951A1 Polypeptides homologous to VEGF and BMP1 |
| 01/21/2009 | EP2016950A1 Pharmaceutical composition comprising an exedin-4 peptide |
| 01/21/2009 | EP2016948A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 01/21/2009 | EP2016945A1 Pharmaceutical containing thiazole derivative as active ingredient |
| 01/21/2009 | EP2016942A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 01/21/2009 | EP2016940A1 Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
| 01/21/2009 | EP2016938A1 Preparation of submicron sized particles via dispersion and solevnt or liquid phase removal |
| 01/21/2009 | EP2015778A1 Healing composition |
| 01/21/2009 | EP2015777A2 Use of organic compounds |
| 01/21/2009 | EP2015759A2 Combination therapy |
| 01/21/2009 | EP2015753A2 Inhibition of hiv infection through chemoprophylaxis |
| 01/21/2009 | EP1641262B1 Circuit for processing video signal containing information such as closed caption |
| 01/21/2009 | EP1626731B1 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 01/21/2009 | EP1307588B1 Method for diagnosing or determining a risk for psychosis comprising determining an heterozygous mutation of methylenetetrahydrofolate reductase (MTHFR) |
| 01/21/2009 | EP1023907B1 Medicinal compositions with cholesterol-lowering effect |
| 01/21/2009 | EP0981352B1 Use of aplidine for the treatment of cardiovascular diseases |
| 01/21/2009 | EP0946155B2 Pharmaceutical composition for treating fecal incontinence |
| 01/21/2009 | CN101351462A 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1(VR1) activity |
| 01/21/2009 | CN101351227A Pharmaceutical composition for application to nail |
| 01/21/2009 | CN101348467A Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 01/21/2009 | CN101347621A Medicament composition for treating respiratory disease |
| 01/21/2009 | CN101347620A Medicament composition and use thereof in preparing medicament for treating glaucoma |
| 01/21/2009 | CN101347619A Medicament composition and use thereof in preparing medicament for treating inflammation of eye section |
| 01/21/2009 | CN101347618A Medicament composition for treating respiratory disease |
| 01/21/2009 | CN101347434A Medicament composition containing renin inhibitor and acidum folicum compound and uses thereof |
| 01/21/2009 | CN101347427A Compound of losartan compound or its medical salt and calcium channel blocker or its medical salt |
| 01/21/2009 | CN100453118C Antientity tumour medicinal composition containing topoenzyme inhibitor |
| 01/21/2009 | CN100453117C Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| 01/21/2009 | CN100453116C Process for preparing compound aminophylline tablet |
| 01/21/2009 | CN100453078C Method for treating primary insomnia |
| 01/20/2009 | US7479579 Genetically engineered rodent comprisingamyloid precursor protein mutation for use as tool in screening therapeutic agents for treatment of neurodegenerative diseases |
| 01/20/2009 | US7479564 e.g. 6-ethyl-5-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-5H-[1,3]dioxolo[4,5-f]benzimidazole; prostaglandin E2 receptor antagonists; arthritis, hyperalgesia, uterine contraction, digestive peristalsis, awakeness, blood pressure, platelet function, bone metabolism, angiogenesis |
| 01/20/2009 | US7479541 and fusion proteins with green fluorescent protein, used for modulating cell differentiation and apoptosis, including cell formation of tissues |
| 01/20/2009 | US7479535 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation |
| 01/20/2009 | US7479505 Administering taurolidine, taurultam, or a biologically active derivative to mammal to directly contact tumor cell at dosage sufficient to induce cell death by apoptosis; side effect reduction |
| 01/20/2009 | US7479498 Treatments for viral infections |
| 01/20/2009 | US7479492 Use combined 5-HT1A agonists and selective serotonin reuptake inhibitors |
| 01/20/2009 | US7479485 Method of treating arrhythmias |
| 01/20/2009 | US7479376 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 01/20/2009 | US7479286 Microbiocides fatty acid mixed with feed |
| 01/20/2009 | US7479279 Use of cytokines of the TGF-β superfamily for the treatment, inhibition and/or diagnosis of skin related disorders |
| 01/20/2009 | US7479278 Troponin I polypeptide fragments and uses thereof |
| 01/20/2009 | US7479254 Kit including a cucurbit(6-10)uril derivative bound to a first material; anda second component that is a ligand that non-covalently binds to the cucurbituril bound to a second material; materials include biomolecules, drugs, catalysts, chromophores, fluorescent materials, phosphors, and cyclophanes |
| 01/20/2009 | CA2586146C Fluorocarbon aerosol medicaments |
| 01/20/2009 | CA2502856C Intermediates for retroviral protease inhibiting compounds |
| 01/20/2009 | CA2465871C Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| 01/20/2009 | CA2415438C .alpha. crystalline form of perindopril tert-butylamine salt |
| 01/20/2009 | CA2383916C Dispersion formulations containing lipase inhibitors |
| 01/20/2009 | CA2376676C Respiratory syncytial virus replication inhibitors |